Carrier Screening Market by Type, Medical Condition, Technology, End-User

List of Tables

[183 Pages Report] The Carrier Screening Market size was estimated at USD 3.07 billion in 2023 and expected to reach USD 3.52 billion in 2024, at a CAGR 14.93% to reach USD 8.13 billion by 2030.

Carrier screening is genetic testing conducted on individuals to determine whether they carry a gene for certain genetic disorders. As carriers, these individuals typically do not exhibit symptoms of the disorder; however, they can pass the gene on to their offspring, who may be at risk of inheriting the disease. Carrier screening is particularly recommended for individuals with a family history of genetic disorders or for those within certain ethnic groups that have a higher prevalence of specific genetic conditions. The increasing prevalence of inherited diseases, growing awareness among potential parents, and supportive government policies aimed at reducing the burden of genetic disorders increase the adoption of carrier screening. However, concerns associated with genetic data, the complexity of genetic counseling, and occasional false positives/negatives could lead to cumbersome follow-up testing and impending market growth. Nevertheless, the integration of next-generation sequencing (NGS) technologies, which allow for comprehensive screening of a large number of genetic conditions at once, the potential for growth in direct-to-consumer genetic testing services, and the expansion of carrier screening programs at the population level in various countries are expected to create potential opportunities for the market growth.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.07 billion
Estimated Year [2024]	USD 3.52 billion
Forecast Year [2030]	USD 8.13 billion
CAGR (%)	14.93%

Type: Expanded carrier screening (ECS) offers a wide overview of genetic health and conditions

Expanded Carrier Screening (ECS) is a comprehensive form of genetic testing that assesses an individual's carrier status for various genetic disorders, typically including those beyond the recommendations for specific ethnicities. This type of screening is designed to simultaneously identify carriers of rare and common genetic conditions, offering a broader assessment that is not limited by ancestry or family history. ECS often informs prospective parents of potential genetic risks that could affect offspring. Customized panel testing allows individuals to select specific genetic conditions for which they wish to be screened based on personal or family history, known carrier status, or particular concerns. This tailored approach ensures that the screening aligns with the specific needs and preferences of the individual. Custom panels can be particularly beneficial for those with a diverse ethnic background or when a rare genetic disorder is suspected in the family lineage. Predesigned Panel Testing involves genetic tests that screen for a predefined list of genetic disorders. These panels are usually created based on the prevalence of certain conditions within a population or based on medical guidelines. They provide a more straightforward and potentially more cost-effective option for carrier screening, as they omit individual customization and focus on a set of conditions deemed necessary by genetic experts. Targeted disease sarrier screening is a focused approach that screens an individual for the carrier status of a specific genetic disorder. This type of screening is often performed when there is a known risk of a particular condition in a family or by ethnicity-based guidelines recommending screening for certain diseases.

End-User: Evolving application of carrier screening in hospitals

Hospitals represent a critical segment within the carrier screening market, provide comprehensive care, and have access to an expansive range of medical specialists and services. Hospitals prefer carrier screening tests incorporating the latest technologies for accurate results. This includes next-generation sequencing (NGS) and microarray-based screenings. Hospitals opt for carrier screenings that cover a wide range of genetic disorders, fulfilling the diverse needs of their patient population. Physician offices and clinics cater primarily to outpatient care and provide a more personalized approach to carrier screening. Due to budget constraints, these establishments prioritize cost-effective solutions while maintaining basic quality standards. Physicians and clinics that might need more specialized staff of larger hospitals prefer simple, easy-to-use carrier screening kits. Hospitals require the most comprehensive test panels and advanced technologies due to the complexity and variety of cases they handle. Physician offices prioritize cost and user-friendliness, given their smaller scale and more direct patient interactions.

Regional Insights

The Americas have a mature market for carrier screening, owing to heightened awareness, technological advancements, and the presence of key market players. In the United States, there is a considerable consumer need for carrier screening due to the diverse genetic makeup of the population and increasing healthcare expenditure. The Affordable Care Act has also impacted the market positively by enabling a broader population to access such screenings. Physician recommendations and the availability of direct-to-consumer genetic testing services influence customer purchasing behavior in these regions. Key patents include advances in sequencing technologies and bioinformatics algorithms for detecting genetic variants. The European market is characterized by consumer needs and purchasing behavior across EU countries, shaped by cultural perspectives, healthcare policies, and genetic counseling practices. Nations with more robust healthcare infrastructure and higher per capita income, such as the Scandinavian countries, exhibit higher adoption rates of carrier screening. Initiatives, including the Horizon Europe program, support research and innovation in the field while GDPR legislates genetic data management. Recent investments are seen in public-private partnerships aimed at enhancing genetic testing technologies. The Middle East is experiencing an increase in demand for carrier screening due to high consanguinity rates, leading to a greater prevalence of genetic disorders. Countries in the Middle East are investing in population-scale genetic projects to improve public health. In Asia-Pacific, carrier screening markets are experiencing rapid growth due to increased investment in healthcare infrastructure. Government initiatives such as the "Healthy China 2030" blueprint and the "Genome Japan" project reflect the country's commitment to advancing genomic medicine. Countries in Asia-Pacific present a vast opportunity, with a burgeoning middle class and increasing healthcare awareness. Patents in the Asia Pacific region are focusing on new genetic technologies and cost-effective testing methods to cater to the growing market. Overall, the region presents a significant potential for growth and innovation in carrier screening.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Carrier Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Carrier Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Carrier Screening Market, highlighting leading vendors and their innovative profiles. These include 23Andme Inc., Abbott Laboratories, Ambry Genetics Corporation by Konica Minolta, Inc., Asper Biogene, Autogenomics Inc. by Prescient Medicine Holdings Inc., BGI Genomics Co., Ltd., Biora Therapeutics, Inc., CENTOGENE N.V., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Gene by Gene, Ltd. by myDNA Inc., GeneDx Holdings Corp., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation by DiaSorin Company, MedGenome Labs Ltd., Myriad Genetics, Inc., Natera, Inc., OPKO Health, Inc., Otogenetics Corporation, Quest Diagnostics Inc., Thermo Fisher Scientific Inc., and TRUE HEALTH LABS.

Market Segmentation & Coverage

This research report categorizes the Carrier Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Expanded Carrier Screening
  - Customized Panel Testing
  - Predesigned Panel Testing

Targeted Disease Carrier Screening

Medical Condition
- Hematological Conditions
- Neurological Conditions
- Pulmonary Conditions

Technology
- DNA Sequencing
- Microarrays
- Polymerase Chain Reaction

End-User
- Hospitals
- Physician Offices & Clinics
- Reference Laboratories

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Carrier Screening Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Carrier Screening Market?

3. What are the technology trends and regulatory frameworks in the Carrier Screening Market?

4. What is the market share of the leading vendors in the Carrier Screening Market?

5. Which modes and strategic moves are suitable for entering the Carrier Screening Market?

Product Code: MRR-034230D3E2DE

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing prevalence of inherited diseases and focus on early disease detection and prevention
  - 5.1.1.2. Rising geriatric population and high risk of chromosomal abnormalities
  - 5.1.1.3. Increasing investment in healthcare infrastructure and government initiatives for the management of genetic disorders
- 5.1.2. Restraints
  - 5.1.2.1. Dearth of skilled professionals and professional services
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging improvements in POC diagnostics
  - 5.1.3.2. Technological advancements in carrier screening
- 5.1.4. Challenges
  - 5.1.4.1. Presence of non-uniform standards and guidelines
5.2. Market Segmentation Analysis
- 5.2.1. Type: Expanded carrier screening (ECS) offers a wide overview of genetic health and conditions
- 5.2.2. End-User: Evolving application of carrier screening in hospitals
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Carrier Screening Market, by Type

6.1. Introduction
6.2. Expanded Carrier Screening
6.3. Targeted Disease Carrier Screening

7. Carrier Screening Market, by Medical Condition

7.1. Introduction
7.2. Hematological Conditions
7.3. Neurological Conditions
7.4. Pulmonary Conditions

8. Carrier Screening Market, by Technology

8.1. Introduction
8.2. DNA Sequencing
8.3. Microarrays
8.4. Polymerase Chain Reaction

9. Carrier Screening Market, by End-User

9.1. Introduction
9.2. Hospitals
9.3. Physician Offices & Clinics
9.4. Reference Laboratories

10. Americas Carrier Screening Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Carrier Screening Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Carrier Screening Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Invitae Completes Sale of Reproductive Health Assets to Natera
- 13.3.2. Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
- 13.3.3. Bio-Techne and Oxford Nanopore Technologies Partner to Bring Innovative Reproductive Health and Carrier Screening Solutions to the Market
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio